Search Results - "Asad, Mohammad Fahad B."

Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC) by Nagasaka, Misako, Asad, Mohammad Fahad B., Al Hallak, Mohammed Najeeb, Uddin, Md. Hafiz, Sukari, Ammar, Baca, Yasmine, Xiu, Joanne, Magee, Dan, Mamdani, Hirva, Uprety, Dipesh, Kim, Chul, Xia, Bing, Liu, Stephen V., Nieva, Jorge J., Lopes, Gilberto, Bepler, Gerold, Borghaei, Hossein, Demeure, Michael J., Raez, Luis E., Ma, Patrick C., Puri, Sonam, Korn, W Michael, Azmi, Asfar S.

“…•In cancer, hyperactive XPO1 promotes the export of important tumor suppressors.•Among 18,218 NSCLC tumors, 26 harbored XPO1 mutations and 24 had…”
Get full text

A Rare Case of CD1a +/CD207 + and S100 - Langerhans Cell Histiocytosis with Multi-System Risk Organ Involvement in Adult by Singh, Rishabh, Nain, Priyanshu, Batool, Saba, Chatterjee, Tulika, Asad, Mohammad Fahad B, Kandula, Manasa

“…Introduction: Langerhans Cell Histiocytosis (LCH) is a rare neoplastic disorder of myeloid dendritic cell precursors, leading to a spectrum of organ…”
Get full text

Heterozygous CTC1 Variants in Acquired Bone Marrow Failure by Shen, Wenyi, Hirsch, Cassandra M., Przychodzen, Bartlomiej P., Mahfouz, Reda Z., Radivoyevitch, Tomas, Williams, Louis, Asad, Mohammad Fahad B., Maciejewski, Jaroslaw P.

“…Germ line (GL) alterations of telomerase machinery genes may lead to inherited telomeropathies, but recent analysis of large control populations revealed that…”
Get full text

Prognostic impact of XPO1 mutations in metastatic non-small cell lung cancer (NSCLC) by Asad, Mohammad Fahad B., Al Hallak, Mohammed Najeeb, Sukari, Ammar, Baca, Yasmine, Xiu, Joanne, Mamdani, Hirva, UPRETY, DIPESH, Kim, Chul, Xia, Bing, Liu, Stephen V., Nieva, Jorge J., Lopes, Gilberto, Borghaei, Hossein, Demeure, Michael J., Raez, Luis E., Ma, Patrick C., Puri, Sonam, Korn, Wolfgang Michael, Azmi, Asfar S., Nagasaka, Misako

“…Abstract only e20533 Background: Nuclear protein transport is essential in guiding the organized traffic of important proteins and RNAs between the nucleus and…”
Get full text

Extent and Clinical Implications of Subclonal Diversity in Paroxysmal Nocturnal Hemoglobinuria by Asad, Mohammad Fahad B, Goyal, Abhinav, Awada, Hassan, Aly, Mai, Hirsch, Cassandra, Clemente, Michael J., Nazha, Aziz, Carraway, Hetty E., Mukherjee, Sudipto, Nagata, Yasunobu, Maciejewski, Jaroslaw P.

“…Paroxysmal Nocturnal hemoglobinuria (PNH) has been traditionally considered a monogenic disease due to somatic mutations in PIGA gene. While selective immune…”
Get full text

Genotype-Resultant Morphology of Myelodysplastic Syndromes (MDS) by Goyal, Abhinav, Mirzaev, Inom, Asad, Mohammad Fahad B., Awada, Hassan, Hirsch, Cassandra M., Makishima, Hideki, Yoshida, Kenichi, Przychodzen, Bartlomiej P., Nazha, Aziz, Mukherjee, Sudipto, Sekeres, Mikkael A., Ogawa, Seishi, Radivoyevitch, Tomas, Scott, Jacob, Maciejewski, Jaroslaw P., Nagata, Yasunobu

“…Morphology has dominated the diagnosis and classification of MDS for decades. With the advent of NGS, morphology is used as a gold standard to assess…”
Get full text

How Somatic Mutations Carve Morphologic Imprint in MDS? by Goyal, Abhinav, Asad, Mohammad Fahad B, Awada, Hassan, Aly, Mai, Hirsch, Cassandra M., Przychodzen, Bartlomiej P., Radivoyevitch, Tomas, Nazha, Aziz, Mukherjee, Sudipto, Sekeres, Mikkael A., Maciejewski, Jaroslaw P., Nagata, Yasunobu

“…Next generation sequencing (NGS) investigations have identified individual mutations that have been useful in differential diagnoses and as biomarkers of…”
Get full text

Biallelic TET2 Inactivation in Myeloid Neoplasia: From Clonal Hierarchy to Clinical Phenotypes by Awada, Hassan, Nagata, Yasunobu, Goyal, Abhinav, Asad, Mohammad Fahad B., Patel, Bhumika J., Hirsch, Cassandra M., Kuzmanovic, Teodora, Adema, Vera, Aly, Mai, Przychodzen, Bartlomiej P., Guan, Yihong, Shen, Wenyi, Williams, Louis, Nazha, Aziz, Abazeed, Mohamed, Sekeres, Mikkael A., Radivoyevitch, Tomas, Haferlach, Torsten, Jha, Babal K., Visconte, Valeria, Maciejewski, Jaroslaw P.

“…Genomic data has led to the identification of bio-markers of morphological features and disease sub-entities in myeloid neoplasia (MN). Somatic TET2 mutations…”
Get full text

Invariant Patterns of Clonal Succession Determines Specific Phenotypic and Clinical Features of Myelodysplastic Syndromes (MDS) by Nagata, Yasunobu, Makishima, Hideki, Yoshizato, Tetsuichi, Suzuki, Hiromichi, Hirsch, Cassandra M., Goyal, Abhinav, Awada, Hassan, Asad, Mohammad Fahad B., Kuzmanovic, Teodora, Przychodzen, Bartlomiej P., Yoshida, Kenichi, Chiba, Kenichi, Tanaka, Hiroko, Shiraishi, Yuichi, Miyano, Satoru, Mukherjee, Sudipto, Radivoyevitch, Tomas, Laframboise, Thomas, Nazha, Aziz, Sekeres, Mikkael A., Haferlach, Torsten, Ogawa, Seishi, Maciejewski, Jaroslaw P.

“…MDS arises through stepwise acquisitions of multiple mutations. Mutation configuration (bi-allelic vs. mono-allelic), specific distributions (hot spot), timing…”
Get full text

Non-Random Interactions between Founder and Subclonal Mutations Shape the Clinical and Morphological Features of MDS by Nagata, Yasunobu, Makishima, Hideki, Hirsch, Cassandra M., Aly, Mai, Goyal, Abhinav, Awada, Hassan, Asad, Mohammad Fahad B, Kuzmanovic, Teodora, Przychodzen, Bartlomiej P., Suzuki, Hiromichi, Yoshizato, Tetsuichi, Yoshida, Kenichi, Chiba, Kenichi, Tanaka, Hiroko, Shiraishi, Yuichi, Miyano, Satoru, Mukherjee, Sudipto, Radivoyevitch, Tomas, Laframboise, Thomas, Nazha, Aziz, Sekeres, Mikkael A., Haferlach, Torsten, Ogawa, Seishi, Maciejewski, Jaroslaw P.

“…The clinical heterogeneity of MDS results from the combinatorial diversity of seemingly random, and thus individually unique, clone mutation hierarchies…”
Get full text

Model Heterogeneity in Predicting Outcomes of Patients with Myelodysplastic Syndromes (MDS) by Al-Issa, Karam, Madanat, Yazan F., Mukherjee, Sudipto, Hirsch, Cassandra M., Gerds, Aaron T., Abuhadra, Nour, Makhoul, Ahed, Awada, Hassan, Asad, Mohammad Fahad B, Goyal, Abhinav, Advani, Anjali S., Kuzmanovic, Teodora, Przychodzen, Bartlomiej P., Carraway, Hetty E., Maciejewski, Jaroslaw P., Sekeres, Mikkael A., Nazha, Aziz

“…Background The outcome of MDS patients (pts) is heterogeneous, with some pts living for years, while others die within a few months of diagnosis. Several…”
Get full text

BCOR Mutations in Myelodysplastic Syndromes (MDS): Mutation Characteristics Impact Clinical Outcomes by Abuhadra, Nour, Al-Issa, Karam, Mukherjee, Sudipto, Hirsch, Cassandra M., Gerds, Aaron T., Jha, Babal K, Adema, Vera, Awada, Hassan, Asad, Mohammad Fahad B, Goyal, Abhinav, Advani, Anjali S., Nagata, Yasunobu, Przychodzen, Bartlomiej P., Carraway, Hetty E., Maciejewski, Jaroslaw P., Sekeres, Mikkael A., Nazha, Aziz

“…Introduction Several recurrent somatic mutations have been identified in myelodysplastic syndromes (MDS) and these mutations play an important role in disease…”
Get full text